OM Pharma SA
General Information
Identification Code: 212362053240-64
Website: www.ompharma.com
Entity Form: Ltd. Company
Registration Category: Companies & groups
Registration Date: 3/15/2024
EP Accredited Number: 1
Mission & Interests
Goals: OUR VISION
OM Pharma aims to be a highly innovative biopharmaceutical company focused on the development and commercialisation of immunotherapeutics against acute and chronic immunological disorders resulting from infections and inflammation.
OUR MISSION
We strive to help patients around the world to live better lives by allowing access to a better management of immunological imbalances.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Climate action
- Education and training
- Public health
- Research and innovation
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: Policy areas:
- Legislation pertaining to public health and environmental issues (e.g revision of general pharmaceutical legislation, antimicrobial resistance, pandemic preparedness and measures to address air quality and pollution)
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Rue du Bois-du-Lan 22
Post Code: 1217
City: Meyrin
Country: SWITZERLAND
Phone:
Indic Phone: 41
Phone Number: 227831211
EU Office
Address: Rue du Bois-du-Lan 22
Post Code: 1217
City: Meyrin
Country: SWITZERLAND
Phone:
Indic Phone: 41
Phone Number: 227831211
Financial Data
Closed Year:
Start Date:
End Date:
Funding Sources:
Contributions:
Total Budget: 0
Grants:
Current Year:
Grants:
Membership Information
Members10 Percent: 1
Members75 Percent: 1
Members: 2
Members F T E: 0.8500000238418579
Structure
Structure Type: Structure
Is Member Of: Reprensenting only own interests, no members affiliated.
Organisation Members: Affiliations through our affiliate company in Switzerland (OM Pharma Suisse SA):
- VIPS (https://vips.ch/fr/)
- scienceindustries (https://www.scienceindustries.ch/en/home)
Current Job Opportunities
mid-levelBrussels, Francefull-time
Posted: 8/21/2025